Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | SLC9A3 | P48764 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32665129 | 0.89 | GLA (0.43) | SMN1; SMN2NPC1RAB9AALDH1A1MMP13 | |
| SCHEMBL32665598 | 0.87 | NPC1 (0.46) | SMN1; SMN2NPC1RAB9AALDH1A1HPGD | |
| SCHEMBL32665531 | 0.87 | GAA (0.43) | SMN1; SMN2MGLLNPC1RAB9AALDH1A1 | |
| SCHEMBL32665453 | 0.86 | NPC1 (0.48) | CA2SMN1; SMN2MGLLNPC1RAB9A | |
| SCHEMBL32665109 | 0.76 | CYP2C9 (0.44) | SMN1; SMN2NPC1RAB9AL3MBTL1 | |
| Hydrochloric Acid SCHEMBL32665128 | 0.75 | NPC1 (0.47) | CA2SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL32665266 | 0.74 | LMNA (0.46) | SMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL32665168 | 0.73 | DRD2 (0.44) | — | |
| SCHEMBL16096276 | 0.72 | MGLL (0.61) | SMN1; SMN2MGLLRAB9AALDH1A1HPGD | |
| SCHEMBL15757532 | 0.70 | MGLL (0.65) | SMN1; SMN2MGLLRAB9AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | TOPAZ THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | RIOX2, ORC3, DCLRE1A | CA2 3681/4885SMN1; SMN2 3601/4885MGLL 4200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.